P CSF Levels of Tau Protein and Beta Amyloid in Diagnosis of Alzheimer ́ S Disease (original) (raw)
Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand
vorapun senanarong
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2011
View PDFchevron_right
Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample
Ekkehard Haen
Neurobiology of Aging, 2006
View PDFchevron_right
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study
Eugeen Vanmechelen
Journal of Neurology, Neurosurgery & Psychiatry, 1998
View PDFchevron_right
CSF p-Tau levels in the prediction of Alzheimer's disease
IJETM Journal
Biology open, 2013
View PDFchevron_right
Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau
Andreas Henkel
Neurobiology of Aging, 2004
View PDFchevron_right
667 Detection of tau proteins in cerebrospinal fluids from Alzheimer's patients
Didier Lefranc
Neurobiology of Aging, 1996
View PDFchevron_right
CSF tau proteins in evaluation of patients with suspected dementia
H. Sarac
2008
View PDFchevron_right
CSF tau proteins in differential diagnosis of dementia
Miljenko Huzak
Translational Neuroscience, 2010
View PDFchevron_right
Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology
Hugo Vanderstichele
Archives of Neurology, 2011
View PDFchevron_right
Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
Robert Cohen
JAMA, 2003
View PDFchevron_right
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
Elisabet Londos
International Journal of Geriatric Psychiatry, 2010
View PDFchevron_right
Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: Beta-amyloid(1-42), tau, phospho-tau-181 and total protein
Josef Marksteiner
Drugs of Today, 2007
View PDFchevron_right
No added diagnostic value of non- phosphorylated tau fraction (p-tau rel ) in CSF as a biomarker for differential dementia diagnosis
Hanne Struyfs, Joery Goossens, Sebastiaan Engelborghs
View PDFchevron_right
Association of Cerebrospinal Fluid Tau Protein in Patients with Alzheimer’s and Non Alzheimer’s Dementias in a Tertiary Level Hospital in Bangladesh
Nasir Rizvi
Clinical and experimental neurology, 2017
View PDFchevron_right
Diagnostic challenges of using CSF assay of tau and beta-amyloid42 in atypical degenerative dementias of the Alzheimer type
Gordon Teichner
Archives of Clinical Neuropsychology, 2003
View PDFchevron_right
Decreased Amyloid 1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
Karen Putnam
2003
View PDFchevron_right
Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan
Koichi Ishiguro
Annals of Neurology, 1998
View PDFchevron_right
Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies
Elisabet Englund
International Journal of Geriatric Psychiatry, 2013
View PDFchevron_right
Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
Constance Delaby
Journal of Neural Transmission, 2022
View PDFchevron_right
Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease A Comparative Cerebrospinal Fluid Study
Niels Andreasen
Archives of General Psychiatry, 2004
View PDFchevron_right
Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P
Sebastiaan Engelborghs
Neurochemistry International, 2009
View PDFchevron_right
CSF-tau, CSF-A�1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer?s disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity
Ulrike Beisiegel
Journal of Neural Transmission, 2003
View PDFchevron_right
Biological markers of Alzheimer?s disease
Marie Sarazin
Arquivos de Neuro-Psiquiatria, 2014
View PDFchevron_right
Interactions between Amyloid-β and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease
Daniela Řípová
Journal of Alzheimer's disease: JAD
View PDFchevron_right
Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid β1–42 and total tau
Fran Borovecki, Goran Simic
Translational Neuroscience, 2013
View PDFchevron_right
Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
Nitish Rai
PLOS ONE, 2016
View PDFchevron_right